Pipeline

February 7, 2020

Company	Drug/Device	Medical Condition	Status
Asklepios BioPharmaceutical	NAN-101	congestive heart failure	phase 1 trial dosing first patient
Immix Biopharma	Imx-110	advanced solid tumors	phase 1b/2a trial dosing first patient in U.S.
Moleculin Biotech	Liposomal Annamycin (annamycin)	relapsed or refractory acute myeloid leukemia	phase 1 trial completed
AIVITA Biomedical	AV-GBM-1	glioblastoma	phase 2 trial enrollment completed
Alkahest	AKST4290	Parkinson’s Disease	phase 2 trial dosing first patient
Minerva Neurosciences	roluperidone	schizophrenia	phase 3 trial enrolling 515 patients in the U.S. and Europe
INVO Bioscience	INVOcell	infertility	phase 3 trial enrolling 180 patients at three sites in the U.S.
VistaGen Therapeutics	AV-101	dyskinesia in Parkinson's Disease patients	phase 2 IND awarded by the FDA
GlycoMimetics	GMI-1359	osteosarcoma	Orphan Drug and Rare Pediatric Disease designations granted by the FDA
Aria CV	Aria CV Pulmonary Hypertension System	pulmonary arterial hypertension	Breakthrough Device designation awarded by the FDA
ReAlta Life Sciences	PIC1-dPEG24	hypoxic-ischemic encephalopathy in neonates	Orphan Drug designation awarded by the FDA
EyeYon Medical	EndoArt film implant	chronic corneal edema secondary to endothelial dysfunction	Breakthrough Device designation awarded by the FDA
VIVUS	PANCREAZE (pancrelipase) Delayed Release Capsules	exocrine pancreatic insufficiency due to cystic fibrosis or other conditions	supplemental NDA approved by the FDA
Seqirus	Audenz vaccine	potential pandemic associated with the H5N1 flu virus	approved by the FDA
Aimmune Therapeutics	Palforzia (AR101)	pediatric patients, ages 4 to 17, who have an allergy to peanuts	approved by the FDA